SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Semler Scientific, Inc. (SMLR) trades at a trailing P/E of 4.0. Trailing earnings yield is 25.25%. PEG 0.04 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (4.0); PEG ≤ 1.0 — Peter Lynch undervalued (0.04); analyst target implies upside (+96.8%); earnings yield beats bond yields (25.25%).
- PEG Ratio 0.04 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 25.25% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
- Analyst consensus target $40.00 (+96.8% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 88/100 with 6/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — SMLR
Valuation Multiples
P/E (TTM)4.0
Forward P/EN/A
PEG Ratio0.04
Forward PEGN/A
P/B Ratio0.00
P/S Ratio2.88
EV/EBITDA0.0
Per Share Data
EPS (TTM)$5.13
Book Value / Share$0.00
Revenue / Share$7.05
FCF / Share$0.00
Yields & Fair Value
Earnings Yield25.25%
Dividend Yield0.00%
Analyst Target$40.00 (+96.8%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-1.72 |
$7M |
$-8.5M |
-121.4% |
| 2016 |
$-0.50 |
$7.43M |
$-2.55M |
-34.4% |
| 2017 |
$-0.28 |
$12.45M |
$-1.51M |
-12.1% |
| 2018 |
$0.66 |
$21.49M |
$5.01M |
23.3% |
| 2019 |
$1.88 |
$32.77M |
$15.08M |
46% |
| 2020 |
$1.74 |
$38.6M |
$14.01M |
36.3% |
| 2021 |
$2.12 |
$53.03M |
$17.22M |
32.5% |
| 2022 |
$1.79 |
$56.69M |
$14.33M |
25.3% |
| 2023 |
$2.63 |
$68.18M |
$20.58M |
30.2% |
| 2024 |
$5.13 |
$56.29M |
$40.9M |
72.7% |
